Labiotech.eu
The European Biotech News Website
- Website
- labiotech.eu · all feeds from this site
- Feed URL
https://www.labiotech.eu/feed/
Read it in your FeedListing reader
Or add to: Feedly Inoreader Raw feed
Latest posts
-
Teva’s pipeline in 2027: Can it sustain its transformation?
While Teva is initially known for its generics business, the company is shifting its strategy to build a more innovative pipeline. The post Teva’s pipeline in 2027: Can it sustain its transformation? appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized…
-
ESMO 2026: readouts and highlights at the oncology summit
ESMO 2026 was the hotspot for cancer research readouts, with encouraging trials across indications and therapeutic candidates. The post ESMO 2026: readouts and highlights at the oncology summit appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use…
-
Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3)
In part three of our series, I spoke with Ryan Confer, President and CEO of Genprex, about the company’s move from cancer into diabetes. The post Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3) appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu.…
-
New idiopathic pulmonary fibrosis drugs on the way
There is a lot of research going on in the therapeutic field of idiopathic pulmonary fibrosis, in the hope that more treatments reach patients sooner. The post New idiopathic pulmonary fibrosis drugs on the way appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu.…
-
TROP2 ADCs: The race to capture the next oncology opportunity
Look into the landscape around TROP2 ADCs as frontrunners aim to expand and the next wave aims to develop safer drugs. The post TROP2 ADCs: The race to capture the next oncology opportunity appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or…
-
13 of the best biotech incubators hatching startups in Europe
Discover our top picks of biotech incubators in Europe giving life science startups the boost they need to get off the ground. The post 13 of the best biotech incubators hatching startups in Europe appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized…
-
The stranded asset problem in microbial custom manufacturing
Lonza brings over 40 years of experience in microbial manufacturing, spanning pilot-scale development through commercial production. The post The stranded asset problem in microbial custom manufacturing appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu.…
-
Novavax’s new strategy: Betting its future on partnerships
Delve into Novavax's pipeline and strategy as the company shifts to a partnership-driven model post-COVID-19. The post Novavax’s new strategy: Betting its future on partnerships appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication…
-
Beyond dilation: six biotechs advancing pulmonary hypertension therapies
Discover six companies advancing promising treatments for pulmonary hypertension beyond vasodilators, changing the standards of care. The post Beyond dilation: six biotechs advancing pulmonary hypertension therapies appeared first on Labiotech.eu . © Labiotech UG and…
-
GLP-1 muscle loss: the next battleground in obesity treatment (Part 2 of 3)
In part two of our series, I’m joined by Paul Little, CEO of Atrogi. We talk about what GLP-1s leave unsolved, the science behind ATR-258, and how a small company competes in a market led by giants. The post GLP-1 muscle loss: the next battleground in obesity treatment (Part 2…
-
Oncology biotech news: key moves to watch in October 2026
Delve into Labiotech's October oncology roundup and find out about the news that caught our attention this last month. The post Oncology biotech news: key moves to watch in October 2026 appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or…
-
Shifting the standard: myopia companies to look out for
Medicines are under review in the clinic to treat myopia. Here are five myopia companies in sight of approval for their therapies. The post Shifting the standard: myopia companies to look out for appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use…
-
Novo’s pipeline in 2026: A new plan to reach $23 billion in sales by 2035
Discover Novo's pipeline in 2026, as it recently set out a new plan to reach $23 billion in risk-adjusted pipeline sales by 2035. The post Novo’s pipeline in 2026: A new plan to reach $23 billion in sales by 2035 appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu.…